Dr Milena Čavić

“Milena Čavić holds a Ph.D. in Biochemistry from the University of Belgrade, Serbia and is currently employed at the Institute for Oncology and Radiology of Serbia. She gained international scientific experience at the University of Barcelona, Spain, and at the Research Center Borstel, Germany. Her current research focus involves investigating molecular mechanisms of response and resistance to chemo-, radio-, targeted and immunological anticancer therapies, as well as the advancement and implementation of cancer early detection and screening programs. Dr Čavić serves as the Co-chair of the Diagnostics Working group of the Screening & Early Detection Committee of the International Association for the Study of Lung Cancer (IASLC). Since 2021, she has been nominated as the President of the EACR-affiliated Serbian Society for Cancer Research (SDIR). Dr Čavić is a coordinator of one Horizon Europe Twinning project (STEPUPIORS) and was a participant in one Horizon 2020 MSCA-RISE (LungCARD) and one PROMIS project (TRACEPIGEN) of the Science Fund of the Republic of Serbia. She has served as an expert evaluator of proposals in Horizon (Life sciences panel) and European Cooperation in Science and Technology (COST) programs. She is passionately involved in the education of young scientists as a lecturer and mentor at the University of Belgrade, Serbia and University of Barcelona, Spain.”

Prof. Dr Ieronymos “Makis” Zoidakis

Assistant Professor of Biochemistry at the Biology Department of the National and Kapodistrian University of Athens (NKUA) and Associated Faculty at the Proteomics Facility of the Biomedical Research Foundation, Academy of Athens (BRFAA)

Prof. Zoidakis was born in Belgium and grew up in Athens, Greece. He studied Biochemistry at the University of Liege in Belgium and then moved to UCLA where he obtained his PhD on Biochemistry and Molecular Biology. He worked at the BRFAA Proteomics Facility as a senior research scientist and has expertise in proteomics and enzymology. He has extensive experience in the implementation of EU research projects and has designed training activities related to omics data generation and integration.

Dr Sergi Castellví-Bel

Dr. Sergi Castellví-Bel is the Group Leader of the “Genetic predisposition to Gastrointestinal Cancer” Group at IDIBAPS, Barcelona, Spain; https://www.clinicbarcelona.org/en/idibaps/research-areas/liver-digestive-system-and-metabolism/genetic-predisposition-to-gastrointestinal-cancer). During over 30 years, he has worked on human monogenic/hereditary conditions and more recently on complex human diseases such as colorectal cancer, gastric cancer and pancreatic cancer. He was the Chair of COST Actions BM1206 and CA17118 (2013-2022) and recognized as Group Leader at his institution (2015). In addition, the research activities of Dr. Castellví-Bel have resulted in >200 articles in highly ranked international journals and has attracted a high number of citations (presently 7.933), with an H-index of 49.

Dr Remond J A Fijneman

Dr. Remond J A Fijneman is Principal Investigator and Associate Group Leader of the Translational Gastrointestinal Oncology group at the Netherlands Cancer Institute, Amsterdam, the Netherlands. Research is focused on identification, validation and implementation of diagnostic, prognostic, predictive and disease monitoring biomarkers for colorectal cancer. Main topics of research concern: 1. the impact of DNA Structural Variants on disease pathogenesis, using tumor tissue and tissue-derived organoids. 2. analyses of cell-free circulating tumor DNA as prognostic, predictive, and disease monitoring biomarkers, using clinically well-defined patient cohorts.